[an error occurred while processing this directive] | [an error occurred while processing this directive]
Current status of research on concurrent chemoradiotherapy after surgery for esophageal cancer
Kang Jingjing,Hui Zhouguang
Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract Currently, resectable esophageal cancer is commonly initially treated with surgery in China, but the optimal postoperative treatment remains unclear. Postoperative concurrent chemoradiotherapy can improve local control and reduce distant metastasis and may become the preferred treatment for patients after surgery for esophageal cancer. By summarizing the studies on concurrent chemoradiotherapy after surgery for esophageal cancer, this review points out that postoperative concurrent chemoradiotherapy can improve the overall survival of patients with positive lymph nodes and has tolerable adverse effects, but the populations who can benefit from this treatment, the optimal radiotherapy dosage, target volume, and chemotherapy regimen of postoperative concurrent chemoradiotherapy await further investigation.
Kang Jingjing,Hui Zhouguang. Current status of research on concurrent chemoradiotherapy after surgery for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 534-535.
Kang Jingjing,Hui Zhouguang. Current status of research on concurrent chemoradiotherapy after surgery for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 534-535.
[1]Chen G,Wang Z,Liu XY,et al. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy[J].World J Surg,2007,31(5):1108-1115.DOI:10.1007/s00268-006-0551-1. [2]Liu Q,Cai XW,Wu B,et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma:implications for the clinical target volume design of postoperative radiotherapy[J].PLoS One,2014,9(5):e97225.DOI:10.1371/journal.pone.0097225. [3]Nakagawa S,Kanda T,Kosugi SI,et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy[J].J Am Coll Surg,2004,198(2):205-211.DOI:10.1016/j.jamcollsurg.2003.10.005. [4]Ando N,Iizuka T,Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study-JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.DOI:10.1200/jco.2003.12.095. [5]Ando N,Iizuka T,Kakegawa T,et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus:the Japan Clinical Oncology Group Study[J].J Thorac Cardiovasc Surg,1997,114(2):205-209.DOI:10.1016/S0022-5223(97)70146-6. [6]Zhang SS,Yang H,Xie X,et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma:a meta-analysis of randomized controlled trials and nonrandomized studies[J].Dis Esophagus,2014,27(6):574-584.DOI:10.1111/dote.12073. [7]Chen JQ,Pan JJ,Zheng XW,et al. Number and location of positive nodes,postoperative radiotherapy,and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2012,82(1):475-482.DOI:10.1016/j.ijrobp.2010.08.037. [8]Fok M,Sham JS,Choy D,et al. Postoperative radiotherapy for carcinoma of the esophagus:a prospective,randomized controlled study[J].Surgery,1993,113(2):138-147. [9]Schreiber D,Rineer J,Vongtama D,et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J].J Thorac Oncol,2010,5(2):244-250.DOI:10.1097/JTO.0b013e3181c5e34f. [10]Ténière P,Hay JM,Fingerhut A,et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research[J].Surg Gynecol Obstet,1991,173(2):123-130. [11]Xiao ZF,Yang ZY,Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma:a report of 495 patients[J].Ann Thorac Surg,2003,75(2):331-336.DOI:10.1016/S0003-4975(02)04401-6. [12]Xiao ZF,Yang ZY,Miao YJ,et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy:report of 549 cases[J].Int J Radiat Oncol Biol Phys,2005,62(1):82-90.DOI:10.1016/j.ijrobp.2004.08.046. [13]Zieren HU,Müller JM,Jacobi CA,et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus:a prospective randomized study[J].World J Surg,1995,19(3):444-449.DOI:10.1007/BF00299187. [14]陆进成,钱普东,查文武,等.食管癌根治术后预防性放射治疗随机研究的Meta分析[J].循证医学,2005,5(3):166-168.DOI:10.3969/j.issn.1671-5144.2005.03.010. Lu JCH,Qian PD,Zha WW,et al. The Meta-analysis of Randomized Controlled Trial of Prophylactic Radiotherapy for Esophageal Carcinoma after Curative Resection[J]. J Evid Based Med,2005,5(3):166-168.DOI:10.3969/j.issn.1671-5144.2005.03.010. [15]Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].N Engl J Med,2001,345(10):725-730.DOI:10.1056/NEJMoa010187. [16]Wang DB,Zhang X,Han HL,et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma:a meta-analysis[J].Dig Dis Sci,2012,57(12):3226-3233.DOI:10.1007/s10620-012-2263-8. [17]Kumagai K,Rouvelas I,Tsai JA,et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers[J].Br J Surg,2014,101(4):321-338.DOI:10.1002/bjs.9418. [18]Adelstein DJ,Rice TW,Rybicki LA,et al. Mature results from a phase Ⅱ trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction[J].J Thorac Oncol,2009,4(10):1264-1269.DOI:10.1097/JTO.0b013e3181b26f8e. [19]Daiko H,Hayashi R,Sakuraba M,et al. A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus[J].Jpn J Clin Oncol,2011,41(4):508-513.DOI:10.1093/jjco/hyr012. [20]Mukaida H,Hirai T,Yamashita Y,et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP,5-Fu,and VP-16 for advanced esophageal cancer[J].Jpn J Thorac Cardiovasc Surg,1998,46(1):11-17.DOI:10.1007/BF03217716. [21]Bédard EL,Inculet RI,Malthaner RA,et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma[J].Cancer,2001,91(12):2423-2430.DOI:10.1002/1097-0142(20010615)91:12<2423::AID-CNCR1277>3.0.CO;2-1. [22]Hsu PK,Huang CS,Wang BY,et al. Survival benefits of postoperative chemoradiation for lymph node–positive esophageal squamous cell carcinoma[J].Ann Thorac Surg,2014,97(5):1734-1741.DOI:10.1016/j.athoracsur.2013.12.041. [23]Rice TW,Adelstein DJ,Chidel MA,et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma[J].J Thorac Cardiovasc Surg,2003,126(5):1590-1596.DOI:10.1016/S0022-5223(03)01025-0. [24]Wang ZW,Luan ZP,Zhang WZ,et al. Postoperative chemoradiotherapy improves survival in esophageal squamous cell cancer with extracapsular lymph node extension[J].Neoplasma,2013,61(6):732-738.DOI:10.4149/neo_2014_089. [25]Saito T,Shigemitsu Y,Kinoshita T,et al. Cisplatin,vindesine,pepleomycin and concurrent radiation therapy following esophagectomy with lymph adenectomy for patients with an esophageal carcinoma[J].Oncology,1993,50(4):293-297.DOI:10.1159/000227198. [26]Liu HC,Hung SK,Huang CJ,et al. Esophagectomy for locally advanced esophageal cancer,followed by chemoradiotherapy and adjuvant chemotherapy[J].World J Gastroenterol,2005,11(34):5367-5372.DOI:10.3748/wjg.v11.i34.5367. [27]Chen JQ,Pan JJ,Liu J,et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2013,86(4):671-677.DOI:10.1016/j.ijrobp.2013.03.026. [28]陈俊强,潘建基,李建成,等.淋巴结阳性胸段食管鳞癌术后放化疗临床研究[J].中华放射肿瘤学杂志,2011,20(4):287-290.DOI:10.3760/cma.j.issn.1004-4221.2011.04.008. Chen JQ,Pan JJ,Li JCH,et al. Clinical study of postoperative chemoradiotherapy of thoracic esophageal squamous cell carcinoma with positive lymph nodes[J].Chin J Radiat Oncol,2011,20(4):287-290.DOI:10.3760/cma.j.issn.1004-4221.2011.04.008. [29]Tachibana M,Yoshimura H,Kinugasa S,et al. Postoperative chemotherapy vs.chemoradiotherapy for thoracic esophageal cancer:a prospective randomized clinical trial[J].Eur J Surg Oncol,2003,29(7):580-587.DOI:10.1016/S0748-7983(03)00111-2. [30]曹秀峰,吕进,朱斌,等.局部晚期食管鳞状细胞癌术后放疗和化疗的前瞻性研究[J].中华肿瘤杂志,2010,32(6):452-455.DOI:10.3760/cma.j.issn.0253-3766.2010.06.013. Cao XF,Lyu J,Zhu B,et al. A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J].Chin J Oncol,2010,32(6):452-455.DOI:10.3760/cma.j.issn.0253-3766.2010.06.013. [31]Lv J,Cao XF,Zhu B,et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma[J].World J Gastroenterol,2010,16(13):1649-1654.DOI:10.3748/wjg.v16.i13.1649. [32]Mariette C,Balon JM,Piessen G,et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease[J].Cancer,2003,97(7):1616-1623.DOI:10.1002/cncr.11228. [33]Chen JQ,Zhu J,Pan JJ,et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J].Ann Thorac Surg,2010,90(2):435-442.DOI:10.1016/j.athoracsur.2010.04.002. [34]章文成.胸段食管鳞状细胞癌根治术后复发模式及术后放疗的价值[D].北京:北京协和医学院,2012. Zhang WCH. Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and the value of radiotherapy after radical surgery[D].Beijing:Peking Union Medical College,2012. [35]Lowe SW,Bodis S,McClatchey A,et al.p53 status and the efficacy of cancer therapy in vivo[J].Science,1994,266(5186):807-810.DOI:10.1126/science.7973635. [36]Luthra R,Wu TT,Luthra MG,et al. Gene expression profiling of localized esophageal carcinomas:association with pathologic response to preoperative chemoradiation[J].J Clin Oncol,2006,24(2):259-267.DOI:10.1200/JCO.2005.03.3688. [37]Li CL,Zhang FL,Wang YD,et al. Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer[J].Oncol Lett,2013,5(1):355-359.DOI:10.3892/ol.2012.946. [38]肖泽芬,周宗玫,吕纪马,等.胸段食管癌淋巴结转移规律与术后放疗范围的探讨[J].中华放射肿瘤学杂志,2008,17(6):427-431.DOI:10.3321/j.issn:1004-4221.2008.06.004. Xiao ZF,Zhou ZM,Lyu JM,et al. Rule of lymph node metastasis and proper target of postoperative radiotherapy for thoracic esophageal carcinoma[J].Chin J Radiat Oncol,2008,17(6):427-431.DOI:10.3321/j.issn:1004-4221.2008.06.004. [39]van Heijl M,van Lanschot J,Koppert L,et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)[J].BMC Surg,2008,8(1):21.DOI:10.1186/1471-2482-8-21. [40]Akutsu Y,Shuto K,Kono T,et al. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma[J].Hepatogastroenterology,2012,59(119):2095-2098.DOI:10.5754/hge11952. [41]Funaki H,Miura S,Morioka E,et al. Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer[J].Gan To Kagaku Ryoho,2014,41(12):2384-238. [42]Kawada J,Iwase K,Deguchi K,et al.Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer[J].Gan To Kagaku Ryoho,2012,39(12):2095-2097. [43]Matsumoto H,Hirabayashi Y,Kubota H,et al. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma[J].Anticancer Res,2012,32(5):1827-1831. [44]毕良文,张丽珍,赵滑峰.多西紫杉醇加奈达铂联合同期适形调强放疗治疗食管癌的疗效[J].中华肿瘤杂志,2012,34(9):710-711.DOI:10.3760/cma.j.issn.0253-3766.2012.09.015. Bi LW,Zhang LZH,Zhao HF.Efficacy of combination of docetaxel and nedaplatin with concurrent IMRT in the treatment of esophagus carcinoma[J].Chin J Oncol,2012,34(9):710-711.DOI:10.3760/cma.j.issn.0253-3766.2012.09.015.
2016, Vol. 25 
